(Q37593059)

21 August 2017

1 reference

title

Cardiotoxicity induced by tyrosine kinase inhibitors (English)

1 reference

21 August 2017

George S Orphanos

1

1 reference

21 August 2017

George N Ioannidis

series ordinal

2

1 reference

21 August 2017

Alexandros G Ardavanis

series ordinal

3

1 reference

21 August 2017

publication date

1 January 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

48

1 reference

21 August 2017

issue

7

1 reference

21 August 2017

page(s)

964-970

1 reference

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Effects of myotoxins on skeletal muscle fibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Ultrastructural identification of apoptotic nuclei using the TUNEL technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

AMPK alterations in cardiac physiology and pathology: enemy or ally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Distinctive activation mechanisms and functions for protein kinase Cdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

BNP as a marker of the heart failure in the treatment of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Nilotinib therapy in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860903229124

10.1080/02841860903229124

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference